The Combination of a Novel GLUT1 Inhibitor and Cisplatin Synergistically Inhibits Breast Cancer Cell Growth By Enhancing the DNA Damaging Effect and Modulating the Akt/mTOR and MAPK Signaling Pathways

Breast cancer is the most prevalent cancer and the second leading cause of cancer death in women. Cisplatin is a commonly used chemotherapeutic drug for breast cancer treatment. Owing to serious side effects, the combination of cisplatin with other drugs is an effective strategy to simultaneously re...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Hao-Cheng, Sung, Chieh-Ju, Hsu, Jui-Ling, Leu, Wohn-Jenn, Guh, Jih-Hwa, Kung, Fan-Lu, Hsu, Lih-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160228/
https://www.ncbi.nlm.nih.gov/pubmed/35662690
http://dx.doi.org/10.3389/fphar.2022.879748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160228/
https://www.ncbi.nlm.nih.gov/pubmed/35662690
http://dx.doi.org/10.3389/fphar.2022.879748

Ejemplares similares